Behl, Ajay S <br/><br/>
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.  [electronic resource] 

 -  Journal of the National Cancer Institute  Dec 2012 
 - 1785-95 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1460-2105 
<br/><br/><label>Standard No.: </label>10.1093/jnci/djs433  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Colorectal Neoplasms--drug therapy<br/>Confounding Factors, Epidemiologic<br/>Cost-Benefit Analysis<br/>Decision Support Techniques<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Genetic Testing--economics<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Quality-Adjusted Life Years<br/>Research Design<br/>United States<br/>ras Proteins--genetics